| In Vivo |
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2]. Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2]. Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2]. Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2]. Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2]. Animal Model: Nude mice inoculated with SK-N-FI tumor cells[2] Dosage: 0.04 or 0.1 mg/mouse Administration: Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days Result: Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma[2] Dosage: 0.02, 0.1 or 0.5 mg/mouse Administration: Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days Result: Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. Animal Model: Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2] Dosage: 0.1 or 0.5 mg/mouse Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days Result: Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model. Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. Animal Model: Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2] Dosage: 0.1 or 0.5 mg/mouse Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks Result: Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft. Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma[2] Dosage: 0.5 mg/mouse Administration: Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation Result: Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
|
